WO2002068419A1 - Derive de pyridopyrimidine ou naphthyridine - Google Patents
Derive de pyridopyrimidine ou naphthyridine Download PDFInfo
- Publication number
- WO2002068419A1 WO2002068419A1 PCT/JP2002/001638 JP0201638W WO02068419A1 WO 2002068419 A1 WO2002068419 A1 WO 2002068419A1 JP 0201638 W JP0201638 W JP 0201638W WO 02068419 A1 WO02068419 A1 WO 02068419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- optionally substituted
- represented
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a novel pyridopyrimidine or naphthyridine derivative having cGMP-specific phosphodiesterase (PDE) inhibitory activity (PDEV inhibitory activity) and useful as a medicament, and a method for producing the same.
- PDE cGMP-specific phosphodiesterase
- cGMP an intracellular second messenger
- phosphodiesterase widely distributed in tissues in vivo, but when the PDE activity is inhibited, the intracellular cGMP concentration increases.
- various pharmacological actions such as a vascular smooth muscle relaxing action, a bronchial smooth muscle relaxing action, a platelet aggregation inhibitory action and the like are exhibited.
- compounds having such cGMP-specific PDE inhibitory activity include various diseases caused by dysfunction of cGMP signaling, such as hypertension, angina pectoris, myocardial infarction. It is known to be useful in the treatment of chronic and acute heart failure, pulmonary hypertension (WO 96/05176, etc.), prostatic hypertrophy (Australian Patent Publication 9955977), etc., and furthermore female sexual dysfunction [Vemulapalli et al., Life ' Sciences, Vol. 67, pp. 23-29 (2000) (Life
- Diabetic gastroparesis [Watkins et al., Journal of Investigation, Vol. 106, pp. 373-384 (2000) (J. Clin. Invest.)] Boracholotti et al., Gastroenterology, Vol. 118, pp. 253-257 (2000) (Gastroenterology);], Diarrhea
- sildenafil has also been reported to have side effects such as headache, flushing, gastrointestinal disturbances, rhinitis, color blindness and erectile dysfunction [Irwin et al., The New Zealand Journal of Medicine. ⁇ Medicine, Vol. 338, No. 20, pp. 1397–1404 (1998) (The New England Journal of Medicine), Morales et al., International Research Journal of the Italian Society, Vol. 10 , No. 2, pp. 69-73 (1998)
- the present invention provides a novel pyridopyrimidine or naphthyridine derivative which has excellent phosphodiesterase V (PDE V) P and has a harmful effect, and is useful as a preventive / therapeutic agent for penile erectile dysfunction with few side effects.
- PDE V phosphodiesterase V
- the present invention provides a compound represented by the general formula (I):
- R 1 represents an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted amino group or an optionally substituted lower alkoxy group
- R 2 represents a hydrogen atom or a lower alkyl group
- R 3 represents a hydrogen atom, an optionally substituted lower alkyl group or an optionally substituted heteroaryl group
- R 4 represents a hydrogen atom, a lower alkyl group or a propyloxyl group which may be esterified or amidated;
- R 5 represents an optionally substituted aryl group, an optionally substituted heteroaryl group or a lower alkyl group optionally substituted with a group selected from di-lower alkylamino groups;
- the nitrogen-containing heterocyclic group of the ⁇ heterocyclic group '' is a 5- to 10-membered monocyclic or bicyclic nitrogen-containing heterocyclic group, more specifically, a 5- to 6-membered monocyclic nitrogen-containing group.
- Examples include a heterocyclic group and an 8- to 10-membered bicyclic nitrogen-containing heterocyclic group, and more specifically, a pyrrolyl group, an oxazolyl group, a virazolyl group, a pyrrolyl group, a pyrrolidyl group, and an imidazolyl group.
- Examples of the substituent of the "optionally substituted nitrogen-containing heterocyclic group" for R 1 include a lower alkyl group which may be substituted with a group selected from a hydroxyl group, a halogen atom and a lower alkoxy group. No.
- the substituent in the "optionally substituted amino group" for R 1 includes a lower alkyl group optionally substituted with a heteroaryl group and a lower alkyl group optionally substituted with an aryl group.
- L 0 member monocyclic or bicyclic aromatic hydrocarbon group.
- substituent in the “optionally substituted lower alkoxy group” for R 1 (1) a group selected from a hydroxyl group, a halogen atom and a lower alkoxy group which may be substituted And a lower alkyl group which may be substituted with a heteroaryl group which may be substituted with a group selected from a linear group or (2) a hydroxyl group, a halogen atom and a lower alkoxy group.
- the aryl group and the heteroaryl group mean the same as described above.
- Examples of the substituent in the “optionally substituted lower alkyl group” for R 3 include a nitrogen-containing heterocyclic group. More specifically, in the above R 1 , a nitrogen-containing cyclic group Examples of the group include the groups exemplified above.
- the heteroaryl group in the ⁇ optionally substituted heteroaryl group '' represented by R 3 is the same 5- to 10-membered monocyclic or bicyclic nitrogen-containing aromatic heterocyclic group as described above.
- the substituent means a group selected from a lower alkyl group, a hydroxyl group, a halogen atom and a lower alkoxy group.
- Examples of the arylene group of the “aryl group which may be substituted” represented by R 5 include the same 5- to 10-membered monocyclic or bicyclic aromatic hydrocarbon groups as described above, and specifically, phenyl And naphthyl groups.
- heteroaryl group of the “optionally substituted heteroaryl group” for R 5 examples include the same 5- to 6-membered monocyclic nitrogen-containing aromatic heterocyclic groups as described above. Specifically, pyridyl And pyrimidyl groups.
- R 5 The substituent of the "optionally substituted Ariru group” and “substituted heteroaryl group to good ⁇ ” represented by R 5, for example, hydroxyl, C port Gen atom, a lower alkoxy group, lower alkylene And the like.
- Examples of the carboxyl group esterified in the ⁇ carboxyl group which may be esterified or amidated '' represented by R 4 include a carbonyl group esterified with a lower alkyl group, and an amidated carboxyl group.
- the carboxyl group may be substituted with a hydroxyl group or a 5- or 6-membered monocyclic nitrogen-containing heterocyclic group which may be substituted, a lower alkyl group-substituted amino group or a substituted 5- to 6-membered heterocyclic group.
- a carboxyl group amidated by a 6-membered monocyclic nitrogen-containing heterocyclic group is exemplified.
- amidated carboxyl group examples include, for example, a pyrrolyl group, an oxazolyl group, a bilazolyl group, a pyrrolinyl group, a pyrrolidiel group, an imidazolyl group, a piperidyl group, a piperazolene group, which may be substituted with a lower alkyl group.
- a 5- to 6-membered monocyclic nitrogen-containing heterocyclic group selected from a morpholinyl group, a pyridyl group, a pyridazinyl group, a pyrimigel group, a pyrazinyl group, a triazinyl group, an imidazolidyl-group and a thiazolyl group.
- Examples of the substituent in the “optionally substituted 5- to 6-membered monocyclic nitrogen-containing heterocyclic group” include a lower alkyl group.
- a lower alkyl group means a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propynole, isopropyl, butyl, isobutyl, and tert-butyl.
- the lower alkoxy group means a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, tert-butyloxy and the like.
- the lower anoalkylenedioxy group means a straight-chain or branched-chain alkylenedioxy group having 1 to 6 carbon atoms such as methylenedioxy, ethylenedioxin, and trimethylenedioxy.
- Halogen atom means fluorine atom, chlorine atom, bromine atom and iodine atom.
- preferred compounds are those wherein the substituent in the “optionally substituted nitrogen-containing heterocyclic group” represented by R 1 in the general formula (1) is a hydroxyl group, A lower alkyl group which may be substituted with a group selected from a halogen atom and a lower alkoxy group, wherein the substituent in the "optionally substituted amino group” may be a lower alkyl group which may be substituted with a heteroaryl group.
- aryl group optionally substituted heteroaryl group or di-lower alkylamino group, which may be substituted with a lower alkyl group
- R 5 The aryl group may be a phenyl group which may be substituted with a group selected from a lower alkoxy group, a lower alkylenedioxy group, and a carboxylic acid atom; Compounds in which a good heteroaryl group is a lower alkoxy group and a pyridyl group or a pyrimidyl group which may be substituted by Z or a halogen atom.
- the nitrogen-containing heterocyclic group in the “optionally substituted nitrogen-containing heterocyclic group” represented by R 1 is a pyrrolyl group, an oxazolyl group, a pyrazolyl group, a pyrrolyl group, or a pyrrolidyl group.
- the nitrogen-containing heterocyclic group in the “optionally substituted nitrogen-containing heterocyclic group” represented by R 1 is a group represented by the formula: Or
- the “carboxyl group which may be esterified or amidated” represented by R 4 has the formula: A lower alkyl group which may be substituted with a group represented by the formula: or an amino group which may be substituted with a lower alkyl group; An amino group or a lower alkyl group which may be substituted with a group represented by the formula:
- a “carboxyl group that may be esterified or amidated” represented by R 4 a formula: A lower alkyl group-substituted amino group optionally substituted with a group represented by the formula:
- R 2 is a hydrogen atom
- R 3 is a hydrogen atom
- R 4 is a hydroxyl group or a formula: A lower alkyl group-substituted amino group or a group represented by the formula A carboxyl group amidated by a group selected from amino groups which may be substituted with a group represented by
- R 5 is a lower alkyl group substituted with a lower alkoxy group and / or a phenyl group which may be substituted with a halogen atom.
- R 2 is a hydrogen atom
- R 3 is a hydrogen atom
- R 4 has the formula:
- R 5 is a lower alkoxy group and a phenyl group which may be substituted by Z or a halogen atom.
- examples of the compound that is preferable in terms of pharmacological activity include a compound selected from the following group or a pharmaceutically acceptable salt thereof.
- compounds that are more preferable in terms of pharmacological effect include (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -1 6— [N- ⁇ 4-1 (1,3,5- Trimethyl) pyrazolyl ⁇ pothamamoyl] -1- (3-chloro-4-methoxybenzyl) -17,8-dihydro-7-oxo-pyrido [2,3-d] pyrimidine, or a pharmaceutically acceptable salt thereof The resulting salt.
- the present invention also provides a compound represented by the following formula (VIII) useful as a synthetic intermediate for the compound represented by the above general formula (I):
- R 7 is a halogen atom or a formula:
- R 9 represents an optionally substituted lower alkyl group or an optionally substituted aryl group
- R 2 represents a hydrogen atom or a lower alkyl group
- R 3 represents a hydrogen atom, a lower alkyl group which may be substituted, or a heteroaryl group which may be substituted
- R 4 represents a hydrogen atom, a lower alkyl group or a propyloxyl group which may be esterified or amidated,
- R 5 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a di-lower alkylamino group
- Compound (I) or a pharmacologically acceptable salt thereof and compound (VIII) or a salt thereof of the present invention do not have a length of 1 , R 2 , R 3 , R 4 , R 5 and Z or R 7.
- the compound may exist as an optical isomer based on the asymmetric atom, and the present invention includes all of these optically heterogeneous 1-organisms and mixtures thereof.
- the compound (I) of the present invention can be used in a free form or in the form of a pharmaceutically acceptable salt for pharmaceutical use.
- Pharmaceutically acceptable salts of compound (I) include, for example, inorganic acid salts such as hydrochloride, sulfate, nitrate or hydrobromide, acetate, fumarate, oxalate, citrate And organic acid salts such as methanesulfonate, benzenesulfonate, tosylate and maleate.
- the compound (I) of the present invention or a salt thereof includes any of its inner salts and adducts, solvates and hydrates thereof.
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof can be administered orally or parenterally.
- It can be used as conventional pharmaceutical preparations such as oral and rapid decay preparations.
- These pharmaceutical preparations are prepared by formulating in a conventional manner together with pharmaceutically acceptable excipients, binders, wetting agents, disintegrants, bulking agents and other additives.
- the dose of the compound (I) of the present invention or a pharmaceutically acceptable salt thereof varies depending on the administration method, age of the patient, body weight, and condition.
- the compound (I) of the present invention or a pharmacologically acceptable salt thereof has an excellent selective PDE VP and harmful effect, in addition to erectile dysfunction described above, dysfunction of cGMP signal transmission is also considered.
- Various diseases caused by e.g., pulmonary hypertension, diabetic gastroparesis, hypertension, angina, myocardial infarction, chronic acute acute heart failure, female sexual dysfunction, prostatic hypertrophy, asthma, diarrhea, constipation, Akarashia
- the compound (I) can be produced by the following [Method A] to [Method G].
- R 4 1 represents a hydrogen atom or a lower alkyl group and the other symbols are of the same - have the meaning
- X 1 represents a halogen atom
- R 6 is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted amino group, an optionally substituted lower alkoxy group, a halogen atom or Formula: _SR 9 (R 9 represents an optionally substituted lower alkyl group or an optionally substituted aryl group), R 8 represents a carboxyl-protecting group, and other symbols have the same meanings as described above.
- R 31 represents a lower alkyl group which may be substituted or a heteroaryl group which may be substituted.
- the compound (VI) further has the general formula (3):
- R 5 1 is a lower alkyl group
- R 8 1 represents a protecting group of the force Rupokishiru group and the other symbols are the same meaning
- R 7 is a halogen atom or a formula:
- R 9 represents a lower alkyl group which may be substituted or an aryl group which may be substituted, and other symbols have the same meanings as described above.
- R 7 is a group represented by SR 9 , that is, the general formula (VIII-2):
- Compound (I-11) is obtained by reacting compound (II) with ammonia by the general formula
- a compound represented by the following formula is produced, and if necessary, the compound (2) is allowed to act on the compound (V). Then, the compound (3) is caused to act on the obtained compound, thereby obtaining a compound represented by the general formula ( ⁇ ):
- X 2 represents a halogen atom, and other symbols have the same meanings as described above.
- R 6 is a halogen atom
- compound (4) is acted upon.
- R 6 is a group SR 9
- the compound can be produced by further oxidizing the obtained compound to obtain a compound (IX), and allowing the compound (4) to act on the compound.
- R 4 is a carboxyl group which may be esterified or amidated, and a general formula (I-2):
- R 4 2 represents a carboxyl group which may be esterified or amidated, and other symbols have the same meaning
- R 3 3 represents a substituent on Echiru group R 3, the other symbols are the same meaning
- R 8 2 represents a protecting group of a carboxyl group and the other symbols are the same meaning
- a compound represented by the general formula (VII) or ( ⁇ ′) in which R 3 is a hydrogen atom is reacted with a metal compound of the compound (2) to close the ring, and then oxidized, whereby R 3 is substituted.
- a metal compound of the compound (2) to close the ring, and then oxidized, whereby R 3 is substituted.
- R 7 1 is a halogen atom or the formula:
- R 9 has the same meaning as described above, and other symbols have the same meanings as described above.
- R 7 1 is based on: A SR 9, i.e., the general formula (VI- 2):
- the reaction between compound (II) and compound (1) can be carried out in a solvent in the presence or absence of a deoxidizing agent.
- a deoxidizing agent examples include organic bases such as N, N-diisopropylethylamine, N-methylenomorpholine, triethylamine and pyridine, and inorganic bases such as hydrogenated sodium, sodium carbonate, carbonated carbonate, sodium hydrogencarbonate and the like. Bases and the like can be suitably used.
- Solvents include dimethyl / les / rephoxide, tetra Any solvent that does not inhibit the reaction, such as hydrofuran, tonolene, ethyl acetate / re, chloropho / rem, dimethoxetane, xylene, and ⁇ , ⁇ -dimethylformamide, can be suitably used. This reaction suitably proceeds at ⁇ 10 ° C. to the boiling point of the solvent used, particularly at 0 ° C. to room temperature.
- the reaction for reducing compound (II) to give compound (IV) can be carried out in a suitable solvent in the presence of a reducing agent.
- a reducing agent anoreminidium manganorekari metal such as lithium aluminum hydride, alkali metal borohydride such as lithium borohydride and the like can be preferably used.
- the solvent a solvent that does not inhibit the reaction, such as tetrahydrofuran, dioxane, getyl ether, and dimethoxyethane, can be suitably used. This reaction suitably proceeds at a temperature of from 178 ° C to the boiling point of the solvent used, particularly from a temperature of from 11 ° C to room temperature.
- the reaction of oxidizing compound (IV) to give compound (V) can be carried out in a solvent in the presence of an oxidizing agent.
- the oxidizing agent is not particularly limited as long as it can induce an alcohol to a corresponding carbonyl compound.
- 4-Benzoquinone, pyridium dichromate chromate, pyridimedichromate and the like can be suitably used.
- a solvent that does not inhibit the reaction such as chloroform, toluene, ethyl acetate, 1,2-dichloroethane, methylene chloride, and tetrahydrofuran, can be used as appropriate. This reaction suitably proceeds at 0 ° C to 100 ° C, particularly at room temperature to 70 ° C.
- the reaction of reacting compound (V) with a metal salt of compound (2) to give compound (VI) can be carried out in a suitable solvent.
- a metal salt of the compound (2) a lithium salt or the like can be suitably used.
- a solvent that does not inhibit the reaction such as tetrahydrofuran, dioxane, getyl ether, and dimethoxyethane, can be used as appropriate. This reaction suitably proceeds at 178 ° C to room temperature.
- the reaction of reacting compound (VI) with compound (3) to give compound (VII) is carried out in a suitable solvent in the presence of a base.
- Bases include sodium hydride, potassium tert-butoxide, potassium carbonate, sodium carbonate, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium hydroxide.
- the solvent include tetrahydrofuran, methanol, ethanol, dimethoxetane, N, N-dimethylformamide, dimethyl sulfoxide, getyl ether, dimethoxetane, dioxane, and toluene. It is possible to use a solvent that does not hinder the reaction. This reaction is suitably carried out at a temperature of from 178 ° C to the boiling point of the solvent used, especially from 10 ° C to 60 ° C.
- the ring closure reaction of compound (VII) is performed in a suitable solvent in the presence of a base catalyst.
- the base catalyst include sodium hydroxide, hydroxide hydroxide, lithium hydroxide, sodium methoxide, sodium methoxide, potassium tert-butoxide, sodium hydride and the like.
- the solvent a solvent that does not inhibit the reaction, such as methanol, ethanol, tetrahydrofuran, dimethyl sulfoxide, N, N-dimethylformamide, and the like can be used. This reaction is suitably carried out at a temperature of 0 ° C to the boiling point of the solvent to be used, especially room temperature to 100 ° C.
- the reaction for oxidizing compound (VIII-2) to give compound (K) can be carried out in an appropriate solvent in the presence of an oxidizing agent.
- Oxidizing agents include peracids such as m-chloroperbenzoic acid and peracetic acid, manganese diacid, sodium periodate, hydrogen peroxide, dinitrogen tetroxide, halogen, hydrophenoloxide, iodobenzene acetate, Inorganic oxidizing agents such as t-butyl hypochlorite, sulfuryl chloride and potassium peroxymonosulfate can be suitably used.
- a solvent that does not inhibit the reaction such as chloroform, methylene chloride, dichloromethane, and acetic acid, can be used as appropriate.
- the present reaction suitably proceeds at a temperature of 178 ° C to 50 ° C, particularly, a temperature of 110 ° C to 10 ° C.
- the reaction of reacting compound (VII) or compound (IX) with compound (4) to give compound (1-1) can be carried out in a solvent in the presence or absence of a deoxidizing agent.
- a deoxidizing agent include organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, and pyridine; and inorganic bases such as sodium hydride, sodium carbonate, potassium carbonate, and sodium hydrogencarbonate. It can be suitably used.
- an alkali metal salt such as a sodium salt and a potassium salt can be suitably used.
- Solvents such as N, N-dimethylformamide, tetrahydrofuran, dimethoxyethane, and dimethylsulfoxide do not inhibit the reaction. Any of these solvents can be suitably used. This reaction suitably proceeds at 0 ° C to 150 ° C, particularly at room temperature to 60 ° C.
- the method of producing compound (II) by reacting compound (II) with ammonia is carried out in the same manner as in the reaction of compound (II) with compound (1) in the above-mentioned Method A.
- reaction of reducing the compound (III ') to obtain the compound (IV) can be carried out in the same manner as the reaction of reducing the compound (III) in the above-mentioned Method A to obtain the compound (IV).
- reaction of oxidizing compound (IV) to obtain compound (V ') can be carried out in the same manner as the reaction of oxidizing compound (IV) to obtain compound (V).
- the step of reacting the compound (2) with the compound (V) and the step of further reacting the compound (3) to obtain the compound ( ⁇ ) also include the step of reacting the compound (V) with the compound (2) in the method (1).
- the reaction can be carried out in the same manner as in the reaction between compound (VI) and compound (3).
- the reaction for leading the compound (VIII-3) by ring closure of the compound ( ⁇ ) can be carried out in the same manner as the reaction for leading the compound (VIII-1) by closing the ring of the compound (VII).
- the step of reacting compound (VIII-3) with compound (5) can be carried out in a suitable solvent in the presence of a deoxidizing agent.
- the deoxidizing agent include potassium carbonate, sodium carbonate, cesium carbonate, hydroxylated sodium, sodium hydroxide, sodium hydride, potassium hydride, sodium methoxide, sodium ethoxide, and potassium butoxide.
- the solvent a solvent which does not inhibit the reaction, such as ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, dimethylsulfoxide, toluene, tetrahydrofuran, dioxane and the like can be used. This reaction suitably proceeds at ⁇ 10 ° C. to the boiling point of the solvent used, particularly at room temperature to 60 ° C.
- the oxidation treatment can be carried out in the same manner as in the method of oxidizing compound (VIII-2) in Method A to obtain compound (IX). And reacting the compound (4) with the product of the compound (VIII-3) and the compound (5) or the oxidized product (K) to obtain the compound (I-11). The reaction is carried out in the same manner as in the reaction of the compound (VIII-1) or the compound (IX) with the compound (4) to obtain the compound (I-11).
- Method C The reaction of reacting compound (VI) with a malonic acid lower alkyl ester or malonic acid can be carried out in a suitable solvent in the presence of a base.
- the reaction is further promoted by the addition of a catalytic amount of acid.
- the base include organic bases such as piperidine, pyridine, getylamine, and triethylamine, and inorganic bases such as sodium methoxide.
- the catalytic amount of acid to be added include hydrochloric acid, acetic acid, benzoic acid, and titanium tetrachloride. Are mentioned.
- a solvent that does not inhibit the reaction such as methanol, ethanol, benzene, to / leene, acetonitrile, propioetrile, tetrahydrofuran, or carbon tetrachloride can be used.
- the present reaction suitably proceeds at a temperature of from 150 ° C to 200 ° C, especially from 0 ° C to the boiling point of the solvent used.
- the reaction leading to the compound (VI 11-14) by ring closure suitably proceeds as it is at 50 ° C. to the boiling point of the solvent used.
- the oxidation of the above product is carried out in the same manner as in the above-mentioned method A, in which the compound (VIII-2) is oxidized to the compound (EX), and the compound (VI) is reacted with malonic acid or the like.
- Compound (4) is reacted with the compound (4) to obtain compound (I-12) by reacting compound (4) with compound (VIII-1) or compound (IX) in Method A described above. To obtain the compound (I-11).
- the reaction between compound (V) and compound (6) can be carried out in a suitable solvent.
- a suitable solvent tetrahydrofuran, dioxane, getyl ether and the like can be suitably used.
- the present reaction suitably proceeds at a temperature of 178 ° C to 60 ° C, particularly preferably a temperature of 178 ° C to room temperature.
- the reaction of oxidizing the product to compound (X) can be carried out in a solvent in the presence of an oxidizing agent.
- the oxidizing agent is not particularly limited as long as it is capable of deriving the phenolic compound to a corresponding carbohydrate compound.
- manganese dioxide, parium permanganate, potassium permanganate, 2,3-dichloro-5,6 1,4-Dibenzoquinone, pyridinum chromate chromate, pyridene dichromate and the like can be suitably used.
- a solvent that does not inhibit the reaction such as chlorophonorem, tonolene, ethinole acetate, 1,2-dichloroethane, methylene chloride, and tetrahydrofuran, can be used as appropriate. This reaction suitably proceeds at 0 ° C. to 100 ° C., particularly at room temperature to 70 ° C.
- the reaction between compound (X) and compound (7) is carried out in the presence or absence of a base, It can be carried out in a solvent.
- a base include organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethynoleamine, and pyridine; and inorganic bases such as hydrogenated sodium, sodium carbonate, carbonated carbonate, and sodium hydrogencarbonate.
- organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethynoleamine, and pyridine
- inorganic bases such as hydrogenated sodium, sodium carbonate, carbonated carbonate, and sodium hydrogencarbonate.
- solvent any of ethanol, ⁇ , ⁇ ⁇ -dimethylformamide, tetrahydrofuran, dimethoxyethane, dimethylsulfoxide and the like can be suitably used.
- This reaction suitably proceeds at 0 to 150 ° C, particularly room temperature to 60 °
- the reaction between compound (XI) and compound (8) can be carried out in a suitable solvent in the presence of a base.
- a base as the leaving group L of the compound (8), a trianolyl silinole group, a trialkyl or a triarylphosphonyl group can be mentioned.
- the base include sodium hydride, sodium methoxide, sodium ethoxide, lithium hydroxide, triethylamine, potassium hexamethylsilazide, lithium diisopropylamide, lithium dicyclohexylamide and the like.
- a solvent that does not inhibit the reaction such as tetrahydrofuran, dimethinoresnorolefoxide, tonolen, methanol, ⁇ , ⁇ -dimethylformamide, benzene, dimethoxetane, and tetrahydroethylenediamine can be used.
- the present reaction suitably proceeds at a temperature of from 100 ° C. to the boiling point of the solvent to be used, particularly from 1 78 ° C. to 30 ° C.
- the metal compound (2) examples include a compound prepared from a metal salt of the compound (2) and copper cyanide.
- a solvent that does not inhibit the reaction such as ether, tetrahydrofuran, siloxane, toluene, benzene, and ethanol, can be used as appropriate.
- the present reaction suitably proceeds at a temperature of from 100 ° C to 50 ° C, desirably from 180 ° C to room temperature.
- the oxidation reaction of the obtained compound can be carried out in a suitable solvent in the presence of an oxidizing agent.
- an oxidizing agent diacid manganese, 2,2-dichloro-5,6-dicyano: p-benzoquinone, chloraenole, selenium dioxide, oxygen (air) and the like can be suitably used.
- Solvents include black form, carbon tetrachloride, acetonitrile, Solvents that do not inhibit the reaction, such as N, N-dimethylformamide, -cinone, xylene, tonolene, benzene, dioxane, tetrahydrofuran, nitrobenzene, pyridine, and acetic acid, can be used as appropriate.
- This reaction suitably proceeds at a temperature of from 120 ° C to the boiling point of the solvent used, preferably from room temperature to 100 ° C.
- the reaction of reacting the metal compound of the compound (2) with the compound (I-11) (wherein R 2, Z or R 3 is a hydrogen atom) and the oxidation reaction of the obtained compound are described in the above-mentioned Method E.
- the reaction can be carried out in the same manner as in the reaction of the compound (2) with the metal compound in the above and the oxidation reaction of the obtained compound.
- the step of causing compound (4) to act on compound (VI-1) can be carried out in the same manner as the step of allowing compound (4) to act on compound (VIII-1) in Method A described above.
- the step of oxidizing the compound (VI-2) can be carried out in the same manner as in the step A of oxidizing the compound (VIII-2).
- the step of allowing compound (4) to act on compound ( ⁇ ) comprises the step of:
- the step of reacting compound (3) with compound (XIII) can be carried out in the same manner as the step of reacting compound (3) with compound (VI) in the above-mentioned Method A.
- the step of cyclizing compound (XIV) can be performed in the same manner as the step of cyclizing compound (VII).
- the compound (I) obtained by forcing can be converted into a pharmaceutically acceptable salt thereof, if desired.
- the compound (II) in which R 2 is a lower alkyl group is It can be produced according to the method described in Justus Leibigs Annalen der Chemie (1973), (5-6), 1025-1035, or DE 2064 096. I can do it.
- reaction mixture is poured into a mixture of ice water and citric acid, extracted with ethyl acetate, washed successively with a 10% aqueous solution of citric acid, water and brine, and dried over anhydrous sodium sulfate.
- the solvent is distilled off under reduced pressure, and the residue is washed with n-hexane to obtain 38.34 g of 2-methinolethio-1-41- (3-chloro-4-methoxypentinoleamino) -15-ethoxycarbolpyrimidine. Melting point: 86 ° C.
- the recovered starting material is treated in the same manner as above except for silica gel (Merck; 60 g).
- Trimethinolephosphonoacetic acid (940 ⁇ l) is added to a suspension of sodium hydride (60%, 232 mg) in tetrahydrofuran (45 ml) at 0 ° C. The mixture is stirred at 0 ° C for 1 hour (during which time a colorless salt precipitates).
- 2 -Methylthio-1-formyl-1- (3-chloro-4-methoxypendinoleamino) pyrimidine (1.50 g) is added to the mixture at once, and the mixture is stirred at 0 ° C for 1 hour.
- Lithium aluminum hydride (8 mg) was added to 3-ethoxycarbonyl-4- (3-chloro-4-methoxybenzylamino) -6-cyclomouth pyridine (38 mg) in tetrahydrofuran (3 ml) Add the solution in small portions at 0 ° C and stir the mixture at 0 ° C for 30 minutes. Acetone and then water are added to the mixture, extracted with ethyl acetate, washed with brine and dried over sodium sulfate.
- Lithium aluminum hydride (49 mg) was added little by little at 0 ° C to a mixture of the compound (23 lmg) obtained in the above (1) and tetrahydrofuran (23 ml), and the mixture was stirred at 0 for 2 hours. I do. Water (0.05ml) and 10% sodium hydroxide aqueous solution (0.075 m 1) to 0. Add with C and stir at room temperature for 1 hour. The insoluble matter is filtered off through sodium sulfate, and the filtrate is concentrated in vacuo.
- the compound (I) of the present invention and a pharmacologically acceptable salt thereof have excellent PDE V inhibitory activity, and are useful as preventive and therapeutic agents for penile erectile dysfunction and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02700731A EP1364950A4 (en) | 2001-02-26 | 2002-02-25 | PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE |
KR1020037011135A KR100540623B1 (ko) | 2001-02-26 | 2002-02-25 | 피리도피리미딘 또는 나프틸리딘 유도체 |
MXPA03007623A MXPA03007623A (es) | 2001-02-26 | 2002-02-25 | Derivado de piridopirimidina o naftiridina. |
NZ527741A NZ527741A (en) | 2001-02-26 | 2002-02-25 | Pyridopyrimidine or naphthyridine derivative |
CA002438294A CA2438294C (en) | 2001-02-26 | 2002-02-25 | Pyridopyrimidine or naphthyridine derivative |
AU2002233706A AU2002233706C1 (en) | 2001-02-26 | 2002-02-25 | Pyridopyrimidine or naphthyridine derivative |
US10/647,234 US7078522B2 (en) | 2001-02-26 | 2003-08-26 | Pyridopyrimidine or naphthyridine derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-49879 | 2001-02-26 | ||
JP2001049879 | 2001-02-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/647,234 Continuation US7078522B2 (en) | 2001-02-26 | 2003-08-26 | Pyridopyrimidine or naphthyridine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002068419A1 true WO2002068419A1 (fr) | 2002-09-06 |
Family
ID=18910918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/001638 WO2002068419A1 (fr) | 2001-02-26 | 2002-02-25 | Derive de pyridopyrimidine ou naphthyridine |
Country Status (10)
Country | Link |
---|---|
US (1) | US7078522B2 (ja) |
EP (1) | EP1364950A4 (ja) |
JP (1) | JP4166991B2 (ja) |
KR (1) | KR100540623B1 (ja) |
CN (1) | CN1503797A (ja) |
AU (1) | AU2002233706C1 (ja) |
CA (1) | CA2438294C (ja) |
MX (1) | MXPA03007623A (ja) |
NZ (1) | NZ527741A (ja) |
WO (1) | WO2002068419A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696213B2 (en) | 2006-09-15 | 2010-04-13 | Pfizer Inc | 4-methylpyridopyrimidinone compounds |
US11739077B2 (en) | 2021-11-12 | 2023-08-29 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2006126082A2 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
WO2006126081A2 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2007044813A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
AU2006302148B2 (en) | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
EP2013208B1 (en) * | 2006-04-21 | 2011-06-22 | Pfizer Products Inc. | Pyridin[3,4-b]pyrazinones |
EP2350070A1 (en) | 2008-09-30 | 2011-08-03 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k and mtor |
US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
ES2817448T3 (es) | 2013-03-14 | 2021-04-07 | Icahn School Med Mount Sinai | Compuestos de pirimidina como inhibidores de quinasas |
CN104557730A (zh) * | 2015-01-27 | 2015-04-29 | 江苏嘉逸医药有限公司 | 阿伐那非关键中间体的制备方法 |
WO2017205432A1 (en) * | 2016-05-23 | 2017-11-30 | Dai Lu | Functionalized pyrano[2,3-d]pyrimidin-7-one derivatives and methods for their preparation and use |
CN116669734A (zh) * | 2020-12-25 | 2023-08-29 | 江苏恒瑞医药股份有限公司 | 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法 |
IL312641A (en) * | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
WO2023216910A1 (zh) * | 2022-05-07 | 2023-11-16 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为usp1抑制剂 |
WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
US4229156A (en) * | 1979-01-15 | 1980-10-21 | Abc Concrete Products | Apparatus for making concrete brick having antique appearance |
US5466692A (en) * | 1993-03-24 | 1995-11-14 | American Home Products Corporation | Substituted pyridopyrimidines and antihypertensives |
WO1996016644A1 (en) * | 1994-11-26 | 1996-06-06 | Pfizer Limited | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION |
US5693652A (en) * | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
US5733914A (en) * | 1995-05-03 | 1998-03-31 | Warner-Lambert Company | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5817670A (en) * | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
US6136810A (en) * | 1995-11-21 | 2000-10-24 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1229413A (ja) * | 1967-06-14 | 1971-04-21 | ||
US3560624A (en) * | 1968-10-18 | 1971-02-02 | Merck & Co Inc | Anticoccidial 2-alkylamino-4-amino benzoic acids |
DE2064096C3 (de) | 1970-12-28 | 1979-04-05 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von in 6-Stellmtg substituierten 2,4-Dichlorpyrimidin-S-carbonsSureestern |
JPS5095273A (ja) | 1973-12-24 | 1975-07-29 | ||
US4229456A (en) * | 1977-07-18 | 1980-10-21 | Merck & Co., Inc. | Substituted naphthyridinones and processes for their preparations |
JPS5481299A (en) | 1977-12-09 | 1979-06-28 | Daito Koeki Kk | Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative |
DE3232620A1 (de) * | 1982-09-02 | 1984-03-08 | Hoechst Ag, 6230 Frankfurt | 10-phenyl1-1,3,9-triazaanthracene und diese enthaltendes photopolymerisierbares gemisch |
AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
EP0257102B1 (en) | 1986-02-24 | 1997-11-19 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
ES2114662T3 (es) * | 1993-08-26 | 1998-06-01 | Ono Pharmaceutical Co | Derivados de la 4-aminopirimidina. |
US5661147A (en) | 1993-09-03 | 1997-08-26 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
US5716993A (en) * | 1993-12-27 | 1998-02-10 | Eisai Co., Ltd. | Anthranilic acid derivatives |
NZ290952A (en) | 1994-08-09 | 1998-05-27 | Eisai Co Ltd | Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups |
US5792767A (en) | 1995-01-27 | 1998-08-11 | Abbott Laboratories | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
KR100239800B1 (ko) | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
CA2271157A1 (en) * | 1997-02-05 | 1998-08-06 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
KR20010023089A (ko) * | 1997-08-20 | 2001-03-26 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 단백질 티로신 키나제 및 세포주기 키나제 매개의 세포증식 억제용 나프티리디논 |
JP2000026294A (ja) | 1998-05-07 | 2000-01-25 | Sankyo Co Ltd | アリ―ルウレア又はアリ―ルメチルカルバモイル誘導体を含有する医薬 |
JP2000072751A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
PL357634A1 (en) * | 2000-01-27 | 2004-07-26 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
CZ20022929A3 (cs) * | 2000-03-06 | 2003-02-12 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas |
DE60303009T2 (de) * | 2002-01-22 | 2006-07-13 | Warner-Lambert Co. Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one |
-
2002
- 2002-02-25 JP JP2002047528A patent/JP4166991B2/ja not_active Expired - Fee Related
- 2002-02-25 WO PCT/JP2002/001638 patent/WO2002068419A1/ja active IP Right Grant
- 2002-02-25 NZ NZ527741A patent/NZ527741A/en unknown
- 2002-02-25 KR KR1020037011135A patent/KR100540623B1/ko not_active IP Right Cessation
- 2002-02-25 AU AU2002233706A patent/AU2002233706C1/en not_active Ceased
- 2002-02-25 EP EP02700731A patent/EP1364950A4/en not_active Withdrawn
- 2002-02-25 CA CA002438294A patent/CA2438294C/en not_active Expired - Fee Related
- 2002-02-25 CN CNA028087194A patent/CN1503797A/zh active Pending
- 2002-02-25 MX MXPA03007623A patent/MXPA03007623A/es active IP Right Grant
-
2003
- 2003-08-26 US US10/647,234 patent/US7078522B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
US4229156A (en) * | 1979-01-15 | 1980-10-21 | Abc Concrete Products | Apparatus for making concrete brick having antique appearance |
US5693652A (en) * | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
US5466692A (en) * | 1993-03-24 | 1995-11-14 | American Home Products Corporation | Substituted pyridopyrimidines and antihypertensives |
US5817670A (en) * | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
WO1996016644A1 (en) * | 1994-11-26 | 1996-06-06 | Pfizer Limited | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION |
US5733914A (en) * | 1995-05-03 | 1998-03-31 | Warner-Lambert Company | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6136810A (en) * | 1995-11-21 | 2000-10-24 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof |
Non-Patent Citations (2)
Title |
---|
See also references of EP1364950A4 * |
WILLIAM A. BOLHOFER ET AL.: "Inhibition of gastric acid secretion by 1,8-naphthyridin-2(1H)-ones", J. MED. CHEM., vol. 22, no. 3, 1979, pages 301 - 306, XP002952618 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696213B2 (en) | 2006-09-15 | 2010-04-13 | Pfizer Inc | 4-methylpyridopyrimidinone compounds |
US8273755B2 (en) | 2006-09-15 | 2012-09-25 | Pfizer Inc | 4-methylpyridopyrimidinone compounds |
US8633204B2 (en) | 2006-09-15 | 2014-01-21 | Pfizer Inc. | 4-methylpyridopyrimidinone compounds |
US11739077B2 (en) | 2021-11-12 | 2023-08-29 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20030076706A (ko) | 2003-09-26 |
US7078522B2 (en) | 2006-07-18 |
JP2002322179A (ja) | 2002-11-08 |
AU2002233706C1 (en) | 2005-12-22 |
MXPA03007623A (es) | 2003-12-04 |
EP1364950A4 (en) | 2005-03-09 |
CA2438294C (en) | 2008-10-21 |
KR100540623B1 (ko) | 2006-01-11 |
NZ527741A (en) | 2005-02-25 |
JP4166991B2 (ja) | 2008-10-15 |
US20050101615A1 (en) | 2005-05-12 |
CN1503797A (zh) | 2004-06-09 |
EP1364950A1 (en) | 2003-11-26 |
CA2438294A1 (en) | 2002-09-06 |
AU2002233706B2 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002068419A1 (fr) | Derive de pyridopyrimidine ou naphthyridine | |
WO2001019802A1 (fr) | Composes cycliques aromatiques azotes a six elements | |
CA2166721C (en) | Bicyclic tetrahydro pyrazolopyridines | |
US6818646B2 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
WO2001083460A1 (fr) | Composes cycliques | |
JP2003513977A (ja) | 置換2−アリール−3−(ヘテロアリール)−イミダゾ[1,2−α]ピリミジン類および関連薬剤組成物および方法 | |
EP2158201B1 (fr) | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
JPH08269060A (ja) | ヘテロ環化合物、その製造方法およびそれを含有する医薬品 | |
JP2006508092A (ja) | γ−セクレターゼの阻害のための環状スルファミド | |
KR960011775B1 (ko) | 새로운 피롤 유도체, 이들의 제조방법 및 이들을 포함하는 약제학적 조성물 | |
JPH01500834A (ja) | アザインドール及びインドリジン誘導体、その製造方法及び薬剤としてのその用途 | |
TW460469B (en) | Tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines | |
JP4601038B2 (ja) | インドリルマレイミド類 | |
JP2004083587A (ja) | 医薬組成物 | |
JP3637961B2 (ja) | 芳香族含窒素六員環化合物 | |
TW200922596A (en) | 4,4-disubstituted piperidines | |
FR2911605A1 (fr) | Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique | |
JP4280165B2 (ja) | 水溶性フェニルピリダジン誘導体及びこれを含有する医薬 | |
JPH0342276B2 (ja) | ||
WO1996032394A1 (fr) | DERIVES DE PYRAZOLO[1,5-a]PYRIMIDINE | |
GB2306164A (en) | Furopyridine derivatives | |
FR2523972A1 (fr) | Derives vinyliques substitues de la 1h-pyrazolo-(1,5-a) pyrimidine utiles notamment comme medicaments antiulcerigenes et antisecretoires gastriques et procede de leur preparation | |
AU2001261178B2 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
JPS6038392B2 (ja) | ナフチリジン誘導体およびその製造方法 | |
FR2640975A1 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2438294 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 527741 Country of ref document: NZ Ref document number: 2002233706 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002700731 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/007623 Country of ref document: MX Ref document number: 1020037011135 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10647234 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037011135 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028087194 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002700731 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 527741 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 527741 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020037011135 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002233706 Country of ref document: AU |